<DOC>
	<DOCNO>NCT02930694</DOCNO>
	<brief_summary>The primary purpose study investigate plasma pharmacokinetics bioavailability ( BA ) single dose solid dose formulation 2 different strength JNJ-54175446 ( 50 milligram [ mg ] 100 mg capsule ) relative suspension JNJ-54175446 fasting condition .</brief_summary>
	<brief_title>A Study Evaluate Bioavailability , Safety Tolerability Solid Dosage Formulation Relative Suspension JNJ-54175446 Healthy Male Female Participants</brief_title>
	<detailed_description />
	<criteria>A body mass index ( BMI ) 18 32 kilogram per square meter ( kg/m^2 ) , inclusive ( BMI = weight/height^2 ) Healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) [ inclusive QTcF le equal ( &lt; = ) 450 millisecond ( msec ) males &lt; = 470 msec female ] perform screening admission ( Treatment period 1 ) clinical unit . Minor abnormality ECG , consider clinical significance physician investigator , acceptable . The presence Left Bundle Branch Block ( LBBB ) , atrioventricular ( AV ) Block ( second degree high ) , permanent pacemaker implantable cardioverter defibrillator [ ICD ] lead exclusion Healthy basis clinical laboratory test perform Screening . If result serum chemistry panel [ exclude liver function test ] , hematology [ include coagulation ] , urinalysis outside normal reference range , participant may include investigator judge abnormality clinically significant . This determination must record participant 's source document initialed/signed physician investigator Must willing adhere prohibition restriction specify protocol Must sign inform consent form ( ICF ) indicate understands purpose procedure require study willing participate study History current liver renal insufficiency ( estimate creatinine clearance 60 milliliter per minute [ mL/min ] ) ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic ( include coagulation disorder ) , rheumatologic , psychiatric , metabolic disturbance , inflammatory illness illness Investigator considers exclude participant History hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) positive , clinically active liver disease , test positive HBsAg antiHCV Screening History human immunodeficiency virus ( HIV ) antibody positive , test positive HIV Screening History malignancy within 5 year screen ( exception squamous basal cell carcinoma skin carcinoma situ cervix , malignancy , opinion investigator , write concurrence sponsor 's medical monitor , consider cure minimal risk recurrence ) History least mild drug alcohol use disorder accord Diagnostic Statistical Manual Mental Disorders ( late edition DSM5 ) criterion within 6 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>